This Unstoppable Cancer-Treatment Company's Stock Is on Sale Now

Cancer treatment company Novocure (NASDAQ: NVCR), which uses low-power electrical fields to disrupt the growth of cancer cells, is now trading 50% below its highs. The company has numerous clinical trials of its technology underway, but traders sold the stock lower after its most recent quarterly earnings report came and went without fresh approvals for new indications from the U.S. Food and Drug Administration (FDA). Let's start by addressing the elephant in the room -- the company's need of new regulatory approvals for its tech to be used in treating additional types of cancers.